Monday, November 9, 2026

GBP/EUR Bearish Momentum: 0.81% Down In The Last 5 Sessions

ViaNews Editorial Team

November 13, 2023

GBP/EUR Bearish Momentum: 0.81% Down In The Last 5 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 0.81% for the last 5 sessions. At 23:08 EST on Sunday, 12 November, GBP/EUR (GBPEUR) is $1.14.

GBP/EUR's yearly highs and lows, it's 2.685% up from its 52-week low and 2.854% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.03%, a negative 0.04%, and a positive 0.21%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.23% (last week), 0.18% (last month), and 0.21% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • Eur/usd could feel a bit more pressure – ING. According to FXStreet on Friday, 10 November, "The EUR/USD 2-year swap rate differential has rewidened after Thursday's events and is now close to the 136 bps pre-FOMC low."
  • Eur/usd to recover moderately in 2024 – commerzbank. According to FXStreet on Friday, 10 November, "Economists at Commerzbank expect the EUR/USD pair to regain some ground next year.", "We expect the EUR/USD exchange rate to recover moderately in 2024 (year-end forecast 2024: 1.09). "
  • Eur/usd flirts with weekly low, manages to hold above mid-1.0600s ahead of ecb’s lagarde. According to FXStreet on Friday, 10 November, "Apart from this, the US bond yields and the broader risk sentiment might influence the USD price dynamics, which, in turn, should produce short-term trading opportunities around the EUR/USD pair.", "The US Dollar (USD) stands tall near a one-week high touched on Thursday in reaction to hawkish remarks by several FOMC members, including Federal Reserve (Fed) Chair Jerome Powell, and turns out to be a key factor weighing on the EUR/USD pair. "
  • Eur/usd: weekly forecast 12th November - 18th November - 12 November 2023. According to DailyForex on Sunday, 12 November, "These two reports will be watched closely by investors and affect the EUR/USD in the middle of the week.", "If these support levels can prove they are not vulnerable, speculative influences in the EUR/USD may believe this is evidence that the reversal lower from the 1.07260 area on Thursday to fresh lows on Friday may prove to be solid target area for reversals upwards."
  • Eur/usd price analysis: consolidates its losses above 1.0660 ahead of ecb’s lagarde speech. According to FXStreet on Friday, 10 November, "The EUR/USD pair consolidates its losses during the early European session on Friday. ", " Technically, the EUR/USD pair holds above the key 100-hour Exponential Moving Averages (EMA), suggesting the path of least resistance is to the upside. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com